Canada Research Chair in Human Genetics and Molecular Medicine
University Killam Professor, Department of Medical Genetics, UBC
Author of approximately 900 peer-reviewed publications and invited submissions, Dr. Hayden has focused his research primarily on translational medicine, including genetics of diabetes, lipoprotein disorders, Huntington disease, predictive, personalized medicine and drug development. Dr. Hayden and his research group have identified 10 disease-causing genes which includes the identification of the major gene underlying high-density lipoprotein (HDL) in humans. Dr. Hayden also identified the first mutations underlying Lipoprotein Lipase (LPL) Deficiency and developed gene therapy approaches to treat this condition resulting in the first approved gene therapy product (Glybera) in a major market. Dr. Hayden has been the most cited author in the world on ABCA1, and Huntington Disease since 2006.
Dr. Hayden was the President of Global R&D and Chief Scientific Officer at Teva from 2012-2017. During this time, approximately 35 new products were approved in major markets with many for diseases of the CNS and led the approval of Austedo for chorea in HD, the second drug ever to be approved for HD.
Dr. Hayden is committed to empowering others. In addition to mentoring over 100 graduate students and postdocs, he is also a TED mentor.
Room 3025, Centre for Molecular Medicine and Therapeutics
950 West 28th Avenue
Vancouver, BC V5Z 4H4
@ Copyright 2020 Djavad Mowafaghian Centre for Brain Health Web Design by Signals